- Current report filing (8-K)
January 27 2010 - 4:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 21, 2010
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
(Exact Name
of Registrant as Specified in Charter)
|
|
|
|
|
Massachusetts
|
|
001-33284
|
|
04-0562086
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
160 Second Street, Cambridge, Massachusetts 02142
(Address of Principal Executive Offices, Including Zip Code)
(617) 492-5554
(Registrants Telephone Number,
Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement with Certain Officers.
|
(b) Dr. Yvonne Greenstreet, M.D. resigned from the Board of Directors of Molecular Insight Pharmaceuticals,
Inc. and from its committees, effective January 21, 2010, and David R. Epstein resigned from the Board and from its committees, effective January 26, 2010. Mr. Epsteins and Dr. Greenstreets resignations were due to significantly
increased work commitments at their respective companies. Mr. Epstein recently was promoted to Head of Pharmaceuticals at Novartis and is relocating to Switzerland. Dr. Greenstreet serves as Senior Vice President and Chief of Strategy, Research
and Development at GlaxoSmithKline.
Item 7.01.
|
Regulation FD Disclosure.
|
On January 27, 2010, the Company issued a press release announcing the above-mentioned resignations. A copy of this press release is furnished with this Current Report on Form 8-K and attached hereto as Exhibit 99.1.
Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act
), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01.
|
Financial Statements and Exhibits.
|
(a) Not applicable.
(b) Not applicable.
(c) Not applicable.
(d) Exhibits. The following exhibit is furnished pursuant to Item 7.01:
|
|
|
99.1
|
|
Press Release of Molecular Insight Pharmaceuticals, Inc., dated January 27, 2010.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be
signed on its behalf by the undersigned, hereunto duly authorized, on the 27
th
day of January, 2010.
|
|
|
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/
S
/ C
HARLES
H. A
BDALIAN
,
J
R
.
|
Name:
|
|
Charles H. Abdalian, Jr.
|
Title:
|
|
Senior Vice President and Chief Financial Officer
|
3
Exhibit Index to Current Report on Form 8-K
|
|
|
Exhibit
Number
|
|
|
|
|
99.1
|
|
Press Release of Molecular Insight Pharmaceuticals, Inc., dated January 27, 2010.
|
4
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From May 2024 to Jun 2024
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Jun 2023 to Jun 2024